Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Toxicol Pathol ; 36(3): 472-7, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18413788

RESUMO

To estimate potential human risk of exposure to a food-derived, genotoxic hepatocarcinogen, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), a 2-year carcinogenicity test was conducted using male F344 rats administered MeIQx-containing diet at doses of 0 (control), 0.001, 1, and 100 ppm. The lowest dose 0.001 ppm was established as equivalent to the daily intake of this carcinogen in humans (0.2 to 2.6 microg/man/day). Significant decreases of survival rate and body weight gain were observed in rats treated with 100 ppm MeIQx. Histopathological examination revealed significant induction of hepatocellular carcinomas, adenomas, and development of glutathione S-transferase placental form-positive foci with MeIQx at 100 ppm. Moreover, the incidences of Zymbal's glands carcinoma, mammary fibroadenoma, and subcutaneous fibroma were found significantly increased in a 100 ppm MeIQx group. However, no significant induction of altered preneoplastic hepatocellular foci was observed in 0.001 and 1 ppm groups as compared to the controls. 8-Hydroxy-2'-deoxyguanosine levels in the rat liver DNA of the 100 ppm-treated group were not elevated, but MeIQx-DNA adduct formation increased as compared with the 1 ppm case, albeit without significance. No significant induction of any other neoplastic lesions related to the carcinogen administration was found in MeIQx-administered groups except for 100 ppm. These results imply that 1 ppm may be a no-effect level for MeIQx carcinogenesis.


Assuntos
Adenoma de Células Hepáticas/induzido quimicamente , Carcinógenos/toxicidade , Carcinoma Hepatocelular/induzido quimicamente , Neoplasias Hepáticas/induzido quimicamente , Lesões Pré-Cancerosas/induzido quimicamente , Quinoxalinas/toxicidade , 8-Hidroxi-2'-Desoxiguanosina , Adenoma de Células Hepáticas/patologia , Administração Oral , Ração Animal , Animais , Carcinógenos/química , Carcinógenos/metabolismo , Carcinoma Hepatocelular/patologia , Adutos de DNA/biossíntese , Adutos de DNA/química , Desoxiguanosina/análogos & derivados , Desoxiguanosina/química , Desoxiguanosina/metabolismo , Relação Dose-Resposta a Droga , Glutationa Transferase/metabolismo , Fígado/efeitos dos fármacos , Fígado/enzimologia , Fígado/patologia , Neoplasias Hepáticas/patologia , Longevidade/efeitos dos fármacos , Masculino , Nível de Efeito Adverso não Observado , Lesões Pré-Cancerosas/enzimologia , Lesões Pré-Cancerosas/patologia , Quinoxalinas/química , Quinoxalinas/metabolismo , Ratos , Ratos Endogâmicos F344
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA